Abstract 574: Depletion of regulatory T cells without interruption of IL-2 signaling by antibody against CD25 for enhancing antitumor immunity
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-574
Abstract: Depleting regulatory T cells from the tumor microenvironment is an attractive strategy for enhancing immunotherapy. Here we developed a humanized antibody against CD25 (H11E11-2V1) with Treg-biased binding. This antibody has a medium affinity to CD25… read more here.
Keywords: antibody cd25; regulatory cells; cd25; rg6292 ... See more keywords
Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct110
Abstract: Background RG6292 is the first anti-human CD25 antibody developed to specifically deplete human Tregs while preserving IL-2R STAT5 signaling and Teff activity. Methods Patients with advanced/metastatic solid tumors and without standard treatment options were enrolled… read more here.
Keywords: safety; rash; rg6292; activity ... See more keywords